China SXT Pharmaceuticals (SXTC) Stock Price, News & Analysis

Company Overview

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy. China SXT’s research platform encompasses preclinical discovery, process development and clinical-stage programs, with therapeutic indications such as cancer supportive care, diabetes and other hormone-related conditions. In addition to its internal pipeline, China SXT Pharmaceuticals offers custom peptide manufacturing services under cGMP conditions, supporting both small biotech firms and large pharmaceutical corporations in advancing their own drug candidates.

Headquartered in Nanjing, China, the company operates research and manufacturing facilities equipped for peptide synthesis, analytical development and scale-up production. Its integrated approach—from early discovery through commercial production—facilitates streamlined development timelines and cost efficiencies. China SXT maintains collaborations with academic institutions and contract research organizations to bolster its R&D capabilities.

While its primary market remains mainland China, China SXT Pharmaceuticals continues to explore regulatory pathways and partnership opportunities to expand its global footprint. The company’s management team comprises experienced professionals in biopharmaceutical research, development and regulatory affairs, guiding China SXT’s efforts to bring innovative peptide therapies from laboratory to market.

Key Stats

• Today's Range: $2.18 to $2.44
• 50-Day Range: $1.44 to $2.57
• 52-Week Range: $1.25 to $1,046.98
• Volume: 47,012 shs
• Average Volume: 137,858 shs
• Market Capitalization: $85.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

China SXT Pharmaceuticals Stock Analysis - MarketRank™

China SXT Pharmaceuticals scored higher than 15% of companies evaluated by MarketBeat, and ranked 792nd out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

China SXT Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

China SXT Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

China SXT Pharmaceuticals has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of China SXT Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

China SXT Pharmaceuticals has a short interest ratio ("days to cover") of 0.19, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in China SXT Pharmaceuticals has recently decreased by 20.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

China SXT Pharmaceuticals does not currently pay a dividend.

Dividend Growth

China SXT Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, China SXT Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.95% of the stock of China SXT Pharmaceuticals is held by insiders.

Percentage Held by Institutions

5.02% of the stock of China SXT Pharmaceuticals is held by institutions.

Company Calendar

• Today: 6/19/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SXTC
• CIK: 1723980
• Web: www.sxtchina.com
• Phone: 8652386299087
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.37
• Quick Ratio: 4.24

Sales & Book Value

• Annual Sales: $1.74 million
• Price / Sales: 48.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3,187.45 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 38,220,000
• Free Float: 36,708,000
• Market Cap: $85.23 million
• Optionable: Not Optionable
• Beta: 1.91